Liposomal amphotericin B (AmBisome®) treatment of invasive fungal infections in immunocompromised children: Die Behandlung invasiver Pilzinfektionen bei abwehrgeschädigten Kindern mit liposomalem Amphotericin B (AmBisome®)

Mycoses

Volumn 36, Issue 5-6, 1993, Pages 187-192

  Ringden O ^a   Tollemar, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AmBisome ; antimycotic chemotherapy; antimykotische Chemotherapie; Aspergillose; aspergillosis; Candidose; Candidosis; children; Kinder; liposomal amphotericin B; liposomales Amphotericin B; mycetoma; Myzetom

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; LIPOSOME;

ADOLESCENT; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MALE; MYCETOMA; NEPHROTOXICITY; SIDE EFFECT; SWEDEN;

ADOLESCENT; AMPHOTERICIN B; ASPERGILLOSIS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG CARRIERS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LIPOSOMES; MADUROMYCOSIS; MALE;

EID: 0027428699     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.1993.tb00748.x     Document Type: Article

References (19)

1. Disseminated candidiasis: changes in incidence, underlying diseases and pathology
2. Fungus infections after liver transplantation
3. Chemoprophylaxis of fungal infections
4. Variables predicting deep fungal infections in bone marrow transplant recipients
5. Amphotericin B toxicity. Combined clinical staff conference at the National Institutes of Health
6. A review of complications of Amphotericin B therapy: Recommendations for prevention and management
7. The carrier potential of liposomes in biology and medicine
8. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
9. Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in small unilamellar liposomes (AmBisome®)
10. Surveillance test for the diagnosis of invasive fungal infections in bone marrow transplant recipients
11. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer. A preliminary study
12. Liposomal amphotericin B (AmBisome®): safety data from a phase II/III clinical trial
13. Liposomal Amphotericin‐B (AmBisome®) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation
14. Prophylactic use of liposomal amphotericin B (AmBisome®) against fungal infections. A randomized trial in bone marrow transplant recipients
15. Efficacy of amphotericin B encapsulated in liposomes (AmBisome®) in the treatment of invasive fungal infections in immunocompromised patients
16. Distribution and activitv of amphoterycin B in humans
17. Strategies in the treatment of systemic fungal infections
18. Liposomal amphotericin B treatment in a 9‐month‐old liver recipient